Luteal Phase in Assisted Reproductive Technology.
Level 5 - mechanism / opinion, no new human data
Narrative review of luteal phase physiology and support in ART without systematic search methodology.
PubMed 36304702 · doi:10.3389/frph.2020.595183
What was done
Narrative review describing luteal phase physiology, mechanisms of luteal phase deficiency during controlled ovarian stimulation with gonadotropin-releasing hormone analogs in assisted reproductive technology, and current approaches to luteal support.
What was found
The abstract reports no numerical data. It details the mechanisms by which assisted reproductive technology protocols suppress pituitary luteinizing hormone secretion, disrupting corpus luteum activity and impairing endometrial receptivity, uterine immunity, contractility, and blood flow. It summarizes management strategies involving exogenous progesterone administration, corpus luteum stimulation, and symptomatic approaches for endometrial progesterone resistance.
Why it matters
It summarizes the physiological rationale for luteal phase support in assisted reproductive technology and clarifies mechanisms distinguishing corpus luteum deficiency from endometrial insensitivity.
Limits
As a narrative review, it presents no primary clinical data, quantitative effect estimates, systematic search methods, or comparisons of specific drug regimens and dosages.
Cited by
- supports During the first 12 weeks of pregnancy, the corpus luteum releases progesterone to support endometrial implantation and maintain early pregnancy.